13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001582844
Total reported value
$143.5M
$143.5M
41 檔
34.7%
The Q3 2024 SEC filing reveals that Acuta Capital Partners, LLC held a total portfolio value of $143.5M, covering 41 public equity positions.
In Q3 2024, Acuta Capital Partners, LLC displayed an active expansion posture, initiating 16 new positions and adding to 11 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte Inc | Stock-Other | 12.53% | — | +22.64% | |
| 2 | OCUL | Ocular Therapeutix Inc | Stock-Other | 8.39% | +0.07% | -57.05% | |
| 3 | TRML | Tourmaline Bio Inc | Stock-Other | 6.92% | — | +23.17% | |
| 4 | INSM | Insmed Inc | Stock-Healthcare | 6.36% | — | +49.10% | |
| 5 | ELVN | Enliven Therapeutics Inc | Stock-Other | 6.13% | — | -25.48% | |
| 6 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 5.45% | — | -2.55% | |
| 7 | ACLXGBX | Arcellx Inc | Stock-Other | 4.20% | — | +47.16% | |
| 8 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 4.20% | — | +86.22% | |
| 9 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.97% | -1.80% | EXIT | |
| 10 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 3.45% | +1.27% | -9.09% | |
| 11 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 3.29% | -18.59% | EXIT | |
| 12 | KURA | Kura Oncology Inc | Stock-Other | 3.12% | — | +20.86% | |
| 13 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 3.09% | +6.59% | — | |
| 14 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 2.84% | — | -24.11% | |
| 15 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.68% | -0.13% | -65.03% | |
| 16 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.59% | +0.60% | +47.50% | |
| 17 | ASND | Ascendis Pharma A/S | Stock-Other | 2.54% | — | — | |
| 18 | CMPS | Compass Pathways PLC | Stock-Other | 1.97% | — | — | |
| 19 | ✓ | Mersana Therapeutics Inc | Stock-Other | 1.84% | — | -27.84% | |
| 20 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 1.53% | — | +1.75% | |
| 21 | ✓ | Acelyrin Inc | Stock-Other | 1.45% | — | — | |
| 22 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.36% | — | — | |
| 23 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.34% | — | -78.26% | |
| 24 | GILD | Gilead Sciences Inc | Stock-Healthcare | 1.32% | — | — | |
| 25 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.13% | — | — | |
| 26 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.79% | — | +11.73% | |
| 27 | ✓ | Stock-Other | 0.65% | — | — | ||
| 28 | LQDA | Liquidia CORP | Stock-Other | 0.60% | — | — | |
| 29 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.57% | — | — | |
| 30 | GERN | Geron CORP | Stock-Other | 0.57% | — | — | |
| 31 | CELC | Celcuity Inc | Stock-Other | 0.56% | — | +3.56% | |
| 32 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 0.55% | +1.76% | NEW | |
| 33 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.34% | — | — | |
| 34 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.31% | — | -71.32% | |
| 35 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.29% | — | -12.00% | |
| 36 | CYPH | Cypherpunk Technologies Inc | Stock-Other | 0.25% | — | -38.21% | |
| 37 | CLYM | Climb Bio Inc | Stock-Other | 0.22% | — | — | |
| 38 | BNTC | Benitec Biopharma Inc | Stock-Other | 0.22% | — | — | |
| 39 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.22% | — | — | |
| 40 | ✓ | Third Harmonic Bio Inc | Stock-Other | 0.17% | — | — | |
| 41 | NUVB-WS | Nuvation Bio Inc -cw27 | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte Inc | +5.5% | +22.64% | Add |
| 2 | TRML | Tourmaline Bio Inc | +4% | +23.17% | Add |
| 3 | ASND | Ascendis Pharma A/S | +2.5% | NEW | New buy |
| 4 | INSM | Insmed Inc | +2.3% | +49.10% | Add |
| 5 | ACLXGBX | Arcellx Inc | +2.2% | +47.16% | Add |
| 6 | MREO | Mereo Biopharma Group Pl-adr | +2.2% | +86.22% | Add |
| 7 | CMPS | Compass Pathways PLC | +2% | NEW | New buy |
| 8 | ✓ | Acelyrin Inc | +1.5% | NEW | New buy |
| 9 | EWTX | Edgewise Therapeutics Inc | +1.4% | NEW | New buy |
| 10 | GILD | Gilead Sciences Inc | +1.3% | NEW | New buy |
| 11 | 430 | Terns Pharmaceuticals Inc | +1.2% | +31.88% | Add |
| 12 | ARGX | Argenx Se - Adr | +1.1% | +47.50% | Add |
| 13 | RARE | Ultragenyx Pharmaceutical In | +1.1% | NEW | New buy |
| 14 | WHWK | Whitehawk Therapeutics Inc | +0.8% | — | Unchanged |
| 15 | ✓ | +0.7% | NEW | New buy | |
| 16 | LQDA | Liquidia CORP | +0.6% | NEW | New buy |
| 17 | ✓ | Verve Therapeutics Inc | +0.6% | NEW | New buy |
| 18 | GERN | Geron CORP | +0.6% | NEW | New buy |
| 19 | ARTV | Artiva Biotherapeutics Inc | +0.6% | NEW | New buy |
| 20 | CRNX | Crinetics Pharmaceuticals In | +0.4% | -2.55% | Trim |
| 21 | TECX | Tectonic Therapeutic Inc | +0.3% | NEW | New buy |
| 22 | KURA | Kura Oncology Inc | +0.3% | +20.86% | Add |
| 23 | CLYM | Climb Bio Inc | +0.2% | NEW | New buy |
| 24 | BNTC | Benitec Biopharma Inc | +0.2% | NEW | New buy |
| 25 | TVTX | Travere Therapeutics Inc | +0.2% | NEW | New buy |
| 26 | ✓ | Third Harmonic Bio Inc | +0.2% | NEW | New buy |
| 27 | TRVI | Trevi Therapeutics Inc | +0.1% | +11.73% | Add |
| 28 | ✓ | Helix Acquisition CORP Ii | — | +1.75% | Add |
| 29 | NUVB-WS | Nuvation Bio Inc -cw27 | — | — | Unchanged |
| 30 | SVRA | Savara Inc | — | EXIT | Sold out |
| 31 | CELC | Celcuity Inc | -0.1% | +3.56% | Add |
| 32 | CYPH | Cypherpunk Technologies Inc | -0.1% | -38.21% | Trim |
| 33 | RAPP | Rapport Therapeutics Inc | -0.1% | -12.00% | Trim |
| 34 | CLRBUSD | Cellectar Biosciences Inc | -0.2% | EXIT | Sold out |
| 35 | NAMS | NewAmsterdam Pharma Company N.V. | -0.4% | EXIT | Sold out |
| 36 | RVMD | Revolution Medicines Inc | -0.4% | -18.80% | Trim |
| 37 | PLRX | Pliant Therapeutics Inc | -0.4% | EXIT | Sold out |
| 38 | ORIC | Oric Pharmaceuticals Inc | -0.6% | EXIT | Sold out |
| 39 | TSHA | Taysha Gene Therapies Inc | -1% | -9.09% | Trim |
| 40 | ✓ | Mersana Therapeutics Inc | -1% | -27.84% | Trim |
| 41 | RCKT | Rocket Pharmaceuticals Inc | -1.7% | -24.11% | Trim |
| 42 | ELVN | Enliven Therapeutics Inc | -1.7% | -25.48% | Trim |
| 43 | CRBP | Corbus Pharmaceuticals Holdi | -2.2% | -71.32% | Trim |
| 44 | VRDN | Viridian Therapeutics Inc | -2.2% | EXIT | Sold out |
| 45 | AGIO | Agios Pharmaceuticals Inc | -2.9% | EXIT | Sold out |
| 46 | PRAX | Praxis Precision Medicines I | -3.1% | -65.03% | Trim |
| 47 | SRPT | Sarepta Therapeutics Inc | -3.7% | EXIT | Sold out |
| 48 | DYN | Dyne Therapeutics Inc | -5% | -78.26% | Trim |
| 49 | OCUL | Ocular Therapeutix Inc | -7.6% | -57.05% | Trim |
According to official SEC Form 13F filings, Acuta Capital Partners, LLC reported a total U.S. public equity portfolio value of $143.5M across 41 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PCVX, OCUL, TRML) accounted for 34.7% of total reported equity market value during Q3 2024.
Top New Position Initiated
ASND
市值: $3.1M
Top Position Liquidated / Trimmed
SRPT
前期市值: $4.3M
During Q3 2024, Acuta Capital Partners, LLC's top holdings by market value included PCVX (12.5%)、OCUL (8.4%)、TRML (6.9%). The largest single position, PCVX, represented 12.5% of total portfolio value.
In Q3 2024, Acuta Capital Partners, LLC made 47 total portfolio adjustments, initiating 16 new buys, adding to 11 positions, trimming 12 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.